Shares of Natco Pharma rallied 9 per cent to Rs 920 on the BSE in Tuesday’s intra-day trade after the company launched its first generic version of Revlimid (Lenalidomide capsules) in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the US market. Natco, along with marketing partner Teva, has launched these strengths of lenalidomide.

• Income Tax Refund Grew 46% in April-November 
• Inventurus Knowledge Solutions Ltd IPO GMP, Lot Size, Key Dates & Investing Details
• Swiss National Bank Cuts Interest Rate by 50 Basis Points 
• SolarSquare Secures $40 in Series B Funding Round 
• CEA Maintains 6.5-7% Growth Estimate for FY25

In the above strengths of lenalidomide, capsules are prescribed in adults to treat multiple myeloma in combination with the medicine dexamethasone, certain myelodysplastic syndromes, and mantle cell lymphoma following specific prior treatment, Natco Pharma said in an exchange filing.